Engflag

Caprez

Quick links to important sections

Caprez

Caprez_EN

Method of action: Antianginal, Antihypertensive, Antispasmodic, Hypotensive, Vasodilator

Treatment option: Hypertension, Angina Pectoris, Prinzmetal Angina

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caprez

Quick Facts

Property Description
Active ingredient Amlodipine
Form Tablet, Oral solution, Oral suspension
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
General purpose Cardiovascular support
Origin Synthetic (Small molecule)

What Type of Medicine is Caprez (Amlodipine)?

Caprez is a prescription-only medication whose active component is Amlodipine, a substance categorized as a synthetic small molecule. It is classified as a Calcium Channel Blocker (CCB), specifically belonging to the Dihydropyridine (DHP) subclass. Caprez is a trade name for Amlodipine, a widely recognized antihypertensive agent.

The primary compound in the preparation is Amlodipine, typically stabilized and administered as Amlodipine besylate. Dihydropyridine CCBs are recognized for their action in achieving effective vasodilation through selective action on peripheral blood vessels, which helps to maintain consistent blood flow. This medicine works by helping blood vessels relax. Caprez is a single-ingredient product, offering precise control over the Amlodipine component.

What is the Purpose and General Action of Caprez?

The overall general purpose of Caprez is to promote cardiovascular health by reducing strain on the heart and improving blood flow throughout the circulatory system. This general benefit stems directly from its action on the vascular walls.

Caprez works by inhibiting the entry of calcium ions into the cells of the vascular smooth muscle, preventing contraction and causing the arteries to relax and widen. This process is known as calcium channel antagonism. This mechanism effectively reduces peripheral vascular resistance, a key factor in controlling blood flow dynamics. This action systematically lowers resistance and ensures the heart muscle receives an improved supply of blood and oxygen.

In What Form is Caprez Administered?

Caprez is a medication designed exclusively for oral administration. The most common presentation is the tablet dosage form, but it is also available as a non-tablet form.

In addition to tablets, the active ingredient Amlodipine is manufactured as an oral solution or oral suspension. The availability of these liquid forms ensures flexibility in administration, particularly for patient groups, such as children six years and older, who may require alternatives to solid oral dosage forms for consistent intake.

Regulatory References

  1. European Medicines Agency
  2. Norvasc - referral (EMA)
  3. NIH MedlinePlus Drug Information
  4. Amlodipine: MedlinePlus Drug Information

What side effects are possible with Caprez?

Possible Side Effects and Safety Information

The official safety profile of Caprez (Amlodipine) outlines adverse reactions based on their documented frequency and the affected body system, as classified by regulatory authorities. The most frequently documented adverse reaction is edema (swelling), which is classified as Very Common.

Reactions categorized as Common include those affecting the nervous system (such as headache, dizziness, and somnolence) and general systemic conditions (like fatigue and asthenia). Vascular effects, specifically flushing and palpitations, are also frequently reported.

Regulatory documents also list Very Rare but serious adverse reactions, including severe allergic reactions like angioedema and erythema multiforme, as well as reports of hepatitis or pancreatitis. Of particular note, worsening angina or myocardial infarction can develop after starting the medication or increasing the dose, especially in individuals with severe obstructive coronary artery disease.

Safety notes specify that certain effects, such as dizziness and headache, are reported more frequently at the beginning of treatment. Furthermore, edema is observed to occur in a dose-related manner.

Safety restrictions prohibit the use of Caprez in conditions such as severe hypotension and cardiogenic shock. Caution is required when using the medicine in specific populations, including older adults and patients with hepatic impairment, as reduced drug clearance in these groups may increase systemic exposure and necessitate careful observation.

Overdose and Emergency Response

️ Overdose and When to Seek Help

This section reflects only the officially documented descriptions of overdose and the emergency actions required, as stated in authoritative government regulatory sources.

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations The main manifestations are marked hypotension and excessive peripheral vasodilation. Central nervous system presentations, such as somnolence, dizziness, tremor, and hypoesthesia, are also documented.
Physiological systems affected Primarily the cardiovascular system and secondarily the central nervous system.
Dose-related factors The prolonged nature of overdose effects is linked to the drug’s long elimination half-life of 30 to 50 hours.
Emergency-response statements If massive overdose occurs, initiate active cardiac and respiratory monitoring.
When immediate medical help is required Seek emergency medical attention immediately, and call the Poison Help line for consultation.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Overdosage carries the risk of shock (due to extreme hypotension) and death in severe, unmanaged cases.
Regulatory basis Based on government regulatory documentation (e.g., FDA Prescribing Information, SmPC).
Overdose-context constraints No specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with marked hypotension and excessive peripheral vasodilation, requiring immediate medical attention.
  • Treatment is symptomatic and supportive, often including the administration of fluids and, if unresponsive to conservative measures, vasopressors such as phenylephrine.
  • Due to the long half-life, continuous cardiac monitoring and extended clinical observation are required.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile primarily through its cardiovascular risk, identifying marked hypotension and excessive peripheral vasodilation as the core manifestations. This physiological presentation dictates that immediate emergency medical help must be sought to manage the potential progression to shock. The official guidance mandates symptomatic and supportive treatment and requires extended clinical monitoring because of the drug's prolonged presence in the body.

Therapeutic Uses of Caprez

What Caprez treats: main uses and benefits

Caprez (Amlodipine) is used to manage high blood pressure, certain types of angina, and coronary artery disease. This medication is applied across therapeutic domains involving symptoms related to systemic imbalance (high pressure) and symptoms that create noticeable physiological strain (anginal chest pain).

Primary Therapeutic Uses

Caprez is commonly used in the daily management of hypertension (high blood pressure) for adults and children aged six years and older. It is also used for managing symptomatic relief of angina, including chronic stable angina and vasospastic angina. This supportive therapeutic benefit supports management of the condition to help address associated risks with persistent high pressure and assists with managing the intensity of painful episodes.

The medication supports the goal of lowering and stabilizing elevated blood pressure readings, as well as managing the symptomatic burden associated with documented coronary artery disease.

“The medication assists with maintaining functional stability and general well-being during symptomatic phases.”

Quick Fact: Relief for Symptoms of Strain
Primary focus Management of high systemic blood pressure (hypertension)
Symptomatic relief Management of chest pain, including chronic stable and vasospastic angina
Patient benefit Contributes to improved day-to-day comfort and stability

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Caprez?

Eligibility for using Caprez (Amlodipine) is determined by regulatory guidelines, focusing on absolute contraindications, age, and specific health conditions.

Absolute Contraindications

Caprez must not be used by individuals with a documented hypersensitivity to Amlodipine or any other dihydropyridine derivatives. It is also contraindicated in patients with severe hypotension, cardiogenic shock, and obstruction of the outflow tract of the left ventricle (such as high-grade aortic stenosis), as stated in official prescribing information.

Age and Organ Function Restrictions

Population Group Eligibility Status
Adults Established for all labeled indications.
Children 6–17 Years Established for hypertension only. Safety is not established for children under six.
Hepatic Impairment Requires a lower initial dose and extreme caution with titration.
Pregnancy Use is conditional; safety is not established, but may be used if the benefit outweighs the risk.
Lactation Not recommended as the medicine is excreted into human milk.

Use requires caution in older adults and patients with congestive heart failure (NYHA Class III and IV).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Caprez (Amlodipine) is extensively metabolized via the Cytochrome P450 3A4 (CYP3A4) enzyme, which forms the basis for numerous officially documented pharmacokinetic interactions.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Classification Interacting Substances/Products Restriction or Constraint (from Label)
Exposure Increase (Amlodipine) Strong or Moderate CYP3A4 Inhibitors (e.g., Clarithromycin, Verapamil, Diltiazem) May result in a significant increase in Amlodipine systemic exposure (AUC/Cmax).
Exposure Decrease (Amlodipine) CYP3A4 Inducers (e.g., Rifampicin, St. John's wort) May lead to decreased Amlodipine plasma concentrations, affecting efficacy.
Exposure Increase (Other Drug) Simvastatin (Cholesterol-lowering agent) Amlodipine increases Simvastatin exposure; the daily dose of Simvastatin must not exceed 20 mg.
Additive Effect Other Anti-hypertensive Agents (e.g., Beta-blockers, Diuretics), Sildenafil Co-administration may produce enhanced blood pressure lowering effects.

Other Documented Restrictions

  • Contraindicated Combination: Use with intravenous Dantrolene is formally avoided due to the risk of severe hyperkalemia.
  • Food/Herbal Product: The consumption of Grapefruit or Grapefruit juice is not recommended as it may increase the bioavailability of Amlodipine in some patients. Alcohol has a documented additive effect on lowering blood pressure.
  • Population Note: The clinical expression of pharmacokinetic variations may be more pronounced in elderly patients, and clearance is reduced in patients with hepatic impairment, leading to increased systemic exposure.

Mechanism of Action

Caprez, containing Amlodipine, acts by interfering with the process of muscle contraction within peripheral blood vessels, resulting in altered systemic flow dynamics. The mechanism is specific, focusing on cellular ion transport systems.

Selective Calcium Channel Blockade in Arteries

This mechanism involves the targeted inhibition of L-type Voltage-Gated Calcium Channels ( L-VGCCs), which are primarily located on the membranes of vascular smooth muscle cells. Amlodipine acts as an antagonist, physically blocking the influx of extracellular calcium ions ( Ca^2+) required to initiate muscle contraction. This action is preferential for arterial channels over cardiac channels, and the drug’s action profile is preferential for the vasculature.

Reduction of Peripheral Vascular Resistance

The resulting inhibition of contraction causes the arterial smooth muscle to relax and the vessels to widen (vasodilate). This systemic widening effectively reduces the overall Peripheral Vascular Resistance (PVR), which is the force the blood must overcome to circulate. Lowering PVR is the physiological step that results in decreased systemic resistance opposing cardiac output.

Dosage and Administration Information

How to Use Caprez (Amlodipine): Administration Guidelines

Caprez (Amlodipine) is used according to specific, standardized instructions. These guidelines define the proper way the medicine is administered and dosed for its approved uses.

Caprez is for oral administration and is available in tablet strengths of 2.5 mg, 5 mg, and 10 mg, as well as in liquid forms (oral solution/suspension). The medication is taken once daily at the same time each day, and it can be taken with or without food.

Standard Dosing and Adjustment Protocol

The standard protocol involves starting at a low dose and adjusting slowly. The usual initial dose for adults is 5 mg once daily. The typical maintenance dose range is 5 mg to 10 mg once daily, with the maximum dose being 10 mg once daily. Dosage adjustments, or titration, should be gradual, with a recommended period of 7 to 14 days between dose increases to assess response.

Administration for Specific Populations

Population Group Labeled Starting Dose Recommendation Maximum Dose
Older Adults May start at 2.5 mg once daily 10 mg once daily
Hepatic Impairment May start at 2.5 mg once daily 10 mg once daily
Pediatric (6–17 yrs) Start at 2.5 mg once daily 5 mg once daily

For patients with renal impairment, specific dosage adjustments are typically not required. If a dose is missed, the standard practice is to skip the missed dose entirely and take the next dose at the regular time; a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Caprez (Amlodipine)

Evidence for Use in Managing High Blood Pressure (Hypertension)

Caprez (Amlodipine) was studied for its use in patients with high blood pressure (hypertension). Clinical trials have examined the changes in elevated blood pressure readings. These studies monitored biomarkers like SBP and DBP, as well as outcomes related to systemic or functional imbalance, such as patterns in the reported occurrence of cardiovascular events. The findings describe patterns observed in the studies related to blood pressure levels recorded in the studied populations.

Evidence for Use in Managing Angina and Symptomatic Relief

Caprez was evaluated in research that explored its use in patients with Angina (a condition involving outcomes related to physical discomfort). Research examined outcomes related to Chronic Stable Angina and Vasospastic Angina in patients treated with Caprez. Studies monitored functional measures, including the duration of exercise recorded before symptoms became noticeable. The research base for Vasospastic Angina is more limited than that for chronic stable angina.

Evidence in Special Populations and Long-Term Data

Children aged six years and older with high blood pressure were observed in specific clinical trials. Research examined the patterns of blood pressure monitoring and reported blood pressure readings in this specific age group. Data also exists regarding older adults, where Amlodipine was evaluated in studies examining patterns of change in measured outcomes.

However, long-term effects are not fully established across all indications, particularly concerning the durability of the findings for symptomatic relief over many years. Data for certain groups remain insufficient, especially for patients with severe heart failure.

Key Studies & References

  1. Amlodipine: MedlinePlus Drug Information (NIH)
  2. Public Assessment Report National Procedure Amlodipine 5 mg Tablets Amlodipine 10 mg Tablets (MHRA - UK)
  3. Exforge (Amlodipine/Valsartan) European Public Assessment Report (EMA)

Frequently Asked Questions (FAQ)

Common questions about Caprez (FAQ)

Q: What is Caprez used for?

Caprez is indicated for the management of chronic mild to moderate conditions, as defined by its official regulatory labeling. Always consult your healthcare provider for the specific approved uses of this medication in your case.

Q: How quickly will Caprez start working?

Clinical information suggests that the time to achieve the full therapeutic effect may vary between individuals. Some patients may observe changes within a few weeks, while others might take longer. The prescribing information does not guarantee a specific onset time.

Q: Is Caprez safe for long-term use?

The long-term safety profile of Caprez has been evaluated in controlled studies. Your healthcare provider will weigh the potential benefits against any possible risks and determine if it is appropriate for you to continue treatment. Regular check-ups are typically recommended during extended therapy.

Q: What should I do if I miss a dose of Caprez?

If you miss a dose, you should refer to the specific instructions provided by your pharmacist or prescribing healthcare professional. The product label usually provides general guidance, but individualized advice is necessary. Do not attempt to take a double dose to make up for a missed one.

How should Caprez be stored and disposed of?

Caprez (Amlodipine) must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F). The medication must be kept in its original container, tightly closed, and stored in a dry place protected from light and excessive moisture. It is strictly prohibited to freeze Caprez or store it in high-humidity areas, such as the bathroom. The tablets must not be crushed. To prevent accidental ingestion, Caprez must be stored out of the sight and reach of children and pets.

Disposal must adhere to official guidelines. Unused or expired medication should not be flushed down the toilet or thrown in household trash without following instructions. Patients should utilize a drug take-back program or consult a pharmacist for proper disposal, especially since Amlodipine is recognized as being toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCroatia (Hrvatska)

flagGeorgia

Equivalent of Caprez found in:

A-Z Index: